David Alan Campbell - Jan 2, 2025 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
President and CEO, Director
Signature
/s/ James Pennington, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jan 2, 2025
Transactions value $
$0
Form type
4
Date filed
1/3/2025, 08:10 PM
Previous filing
Dec 27, 2024
Next filing
Jan 8, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Award $0 +81K +37.32% $0.00 298K Jan 2, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock option (right to buy) Award $0 +284K $0.00 284K Jan 2, 2025 Common Stock 284K $53.24 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.
F2 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.